Organization | Aviragen Therapeutics

Aviragen Therapeutics Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Melbourne Australia (1984)

Status: Acquired by Vaxart (2017)

Organization Overview

First Clinical Trial

2007

NCT00311714

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Drugs in Phase 4 Trials (3)

Key: Aviragen Therapeutics (0) Acquired (3)

atorvastatin (lipitor) (1 trial)

calcium (2 trials)

sevelamer (renagel) (1 trial)

Drugs in Phase 3 Trials (3)

Key: Aviragen Therapeutics (0) Acquired (3)

nicvax (8 trials)

s. aureus type 5 & 8 capsular polysaccharide conjugate (6 trials)

staph aureus types 5 and 8 conjugate vaccine (1 trial)

Drugs in Phase 2 Trials (11)

Key: Aviragen Therapeutics (3) Acquired (8)

ap611074 (2 trials)

bivalent rluks-pv / rat (1 trial)

Enzaplatovir (3 trials)

i-123-5-ia85380 (1 trial)

laninamivir octanoate hydrate (6 trials)

nicotine (nicorette) (2 trials)

s. aureus immune globulin (1 trial)

staphylococcus aureus immune globulin (1 trial)

staphylococcus aureus toxoids (1 trial)

vapendavir (6 trials)

varenicline (chantix) (1 trial)

Drugs in Phase 1 Trials (4)

Key: Aviragen Therapeutics (2) Acquired (2)

anti-hiv immune serum globulin (human) (1 trial)

bta9881 (1 trial)

cryptosporidium immune whey protein concentrate (1 trial)

midazolam (versed) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Asthma (Phase 2)

Communicable Diseases (Phase 2)

Condylomata Acuminata (Phase 2)

Infections (Phase 2)

Influenza, Human (Phase 2)

Respiratory Syncytial Virus Infections (Phase 1)

Respiratory Tract Infections (Phase 2)

Virus Diseases (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 41
# of Trial APIs: 21